Search results
1 day ago · Vivos Therapeutics' first-quarter revenue decreased to $3.4 million. The company enrolled 50 VIPs, up from 36 in the previous year's quarter. Gross profit stood at $1.9 million with a 57% gross margin. Operating expenses were cut by 22%, leading to a reduced operating loss. Vivos aims to be cash flow positive by the end of 2024 or early 2025.
